Design and operation of a current good manufacturing practices cell-engineering laboratory

Cytotherapy

Volumn 2, Issue 2, 2000, Pages 111-122

  Burger, Scott R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASEPSIS; BACTERIUM CONTAMINATION; BIOMEDICAL ENGINEERING; BIOTECHNOLOGY; CLINICAL LABORATORY; ENVIRONMENTAL SANITATION; GENETIC ENGINEERING; GOOD MANUFACTURING PRACTICE; PROCESS CONTROL; QUALITY CONTROL; REVIEW;

EID: 0033936102     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532400539116     Document Type: Article

References (26)

1. Proposed approach to regulation of cellular and tissue-based products. Docket Number 97N-0068, February 28, 1997.
2. Harvath L. FDA's proposed regulatory approach to regulation of hematopoietic stem/progenitor cell products. Cytotherapy 1999;1:358-9.
3. Current good manufacturing practice for finished pharmaceuticals. 21 CFR 211.
4. Zuck TF. Current good manufacturing practices. Transfusion 1995;35:955-66.
5. Williams RL. Big biotech: designing the plant of the future. BioPharm 1997;11:44-51.
6. Hamers MN. Multiuse biopharmaceutical manufacturing. Bio/Technology 1993;11:561-70.
7. Odum JN. Building quality into GMP facilities. BioPharm 1993;6:42-52.
8. Bader FG, Blum A, Garfinkle BD, et al. Multiuse manufacturing facilities for biologicals. BioPharm 1992;6:32-40.
9. Hill D, Beatrice M. 1989. Biotechnology facility requirements, Part I: Facility and systems design. BioPharm 1989;10:20-6.
10. Kittler EL, Quesenberry PJ. Concept and organization of a clinical gene therapy lab. J Cell Biochem 1995;58:403-9.
11. Tolbert WR, Merchant B, Taylor JA, Pergolizzi RG. Designing an initial gene therapy manufacturing facility. BioPharm 1996;11:32-40.
12. Islam KB, Blomberg P, Wikstrom K, Smith CI. An academic centre for gene therapy research with clinical grade manufacturing capability. Ann Med 1997;29:579-83.
13. FDA Forum 1996 on Gene Therapy: Development and Evaluation of Phase I Products, Vector Development. July 11, 1996. The Division of Cellular and Gene Therapies HFM-518 Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD20852, USA.
14. Current Good Manufacturing Practice; Proposed Amendment of Certain Requirements for Finished Pharmaceuticals. Docket No. 95N-0362. Fed Reg 1996;61(87):20104-15.
15. Medical device quality systems manual, center for devices and radiologic health. January 1, 1997. http://www.fda.gov /cdrh/qsr/contnt.html
16. Good Manufacturing Practices (GMP)/Quality System (QS) Regulation, Center for Devices and Radiologic Health. April 17, 1998. http://www.fda.gov/cdrh/devadvice/32.html#top
17. Quality System Regulations. 21 CFR 820.1. June 1, 1997
18. Federal Standard Airborne Particulate Cleanliness Classes in Clean Rooms and Clean Zones (FED-STD-209E). United States Government printing office, 11 Sept. 1992. Revised 15 Dec. 1994.
19. Wilson JD. Setting alert/action limits for environmental monitoring programs. PDA J Pharm Sci Technol 1997; 51:161-2.
20. Sjoholm I. In-process testing and limits. Develop Bio Standard 1997;91:73-8.
21. Microbiological evaluation of clean rooms and other controlled environments. United States Pharmacopoeia, general information chapter 1116. 1995; 1116:1-88.
22. Akers J, Agalloco J. Sterility and sterility assurance. PDA J Pharm Sci Technol 1997;51:72-7.
23. Hertroys R, Van Vught PA, Van De Donk HJ. Moving towards a (microbiological) environmental monitoring programme that can be used to release aseptically produced pharmaceuticals: a hypothesis, a practical programme, and some results. PDA J Pharm Sci Technol 1997;51:52-9.
24. Munson TE, Sorenson RL. Environmental monitoring: regulatory issues. In: Groves MJ, Olson WP, Anisfeld MH, editors. Sterile pharmaceutical manufacturing - applications for the 90's. Buffalo Grove, IL: Interpharm Press, Inc., 1991.
25. Mascotti K, McCullough J, Burger SR. Hematopoietic cell viability measurement: trypan blue vs. acridine orange/propidium iodide. Transfusion. In press.
26. Burger SR. cGMP cell engineering facility design and environmental monitoring. In: Collins N, Read EJ, Gee A, editors. Cellular Therapies. Oxford: Isis Medical Media, 2000. In press